Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EBITDA | -22.74M | -45.03M | -25.51M | -14.50M | -5.46M |
Net Income | -24.59B | -56.20M | -25.33M | -14.49M | -5.46M |
Balance Sheet | |||||
Total Assets | 13.93M | 10.21M | 36.02M | 46.00M | 8.12M |
Cash, Cash Equivalents and Short-Term Investments | 10.55M | 5.75M | 28.38M | 45.69M | 8.07M |
Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Total Liabilities | 4.62M | 17.96M | 7.70M | 1.51M | 578.38K |
Stockholders Equity | 9.31M | -7.75M | 28.32M | 44.49M | 7.54M |
Cash Flow | |||||
Free Cash Flow | -21.89B | -39.97M | -17.31M | -9.13M | -3.97M |
Operating Cash Flow | -21.89B | -39.97M | -17.31M | -9.13M | -3.97M |
Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financing Cash Flow | 26.69B | 17.34M | 4.61K | 46.74M | 12.04M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $7.47B | 0.53 | -62.70% | 2.38% | 14.92% | 0.82% | |
51 Neutral | $29.56M | ― | -70.06% | ― | 146.47% | 57.85% | |
41 Neutral | $35.67M | ― | -853.05% | ― | ― | 34.97% | |
38 Underperform | $66.56M | ― | 78.50% | ― | ― | 55.52% | |
35 Underperform | $20.31M | ― | -246.21% | ― | ― | 44.38% | |
35 Underperform | $51.83M | ― | -280.78% | ― | ― | 68.75% |
On March 26, 2025, Annovis Bio, Inc. received a notice from the New York Stock Exchange (NYSE) indicating non-compliance with the NYSE’s continued listing standards due to its average market capitalization and stockholders’ equity falling below $50 million. The company plans to submit a compliance plan within 45 days, which the NYSE will review to determine if Annovis can meet the standards within an 18-month period. The notice does not affect the company’s business operations or its reporting obligations, and its stock will continue to be traded with a ‘.BC’ designation until compliance is regained.
On February 5, 2025, Annovis Bio Inc. announced the commencement of its pivotal Phase 3 study for the drug buntanetap in early Alzheimer’s disease, marking a significant step toward market approval. The study, which follows promising results from previous trials, is designed to assess both symptomatic and potential disease-modifying effects over an 18-month period and involves over 750 participants across the United States.